BR112012011126A2 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BR112012011126A2
BR112012011126A2 BR112012011126A BR112012011126A BR112012011126A2 BR 112012011126 A2 BR112012011126 A2 BR 112012011126A2 BR 112012011126 A BR112012011126 A BR 112012011126A BR 112012011126 A BR112012011126 A BR 112012011126A BR 112012011126 A2 BR112012011126 A2 BR 112012011126A2
Authority
BR
Brazil
Prior art keywords
volatile
solvent
pharmaceutical composition
active ingredient
component comprises
Prior art date
Application number
BR112012011126A
Other languages
English (en)
Inventor
Francis Davis Adrian
Original Assignee
Futura Medical Developments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futura Medical Developments Ltd filed Critical Futura Medical Developments Ltd
Publication of BR112012011126A2 publication Critical patent/BR112012011126A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"composição farmacêutica" uma composição farmacêutica compreende um ingrediente ativo dissolvido em um sistema carreador essencialmente não aquoso compreendendo componentes voláteis e não voláteis, na qual o componente volátil compreende um não solvente volátil para o ingrediente ativo e um aditivo de solvatação volátil para o não solvente e o componente não volátil compreende um não solvente não volátil e opcionalmente um solvente não volátil para o ingrediente ativo, os não solventes volátil e não volátil compreendendo fluidos de silicone de viscosidade respectivamente diferentes.
BR112012011126A 2009-11-10 2010-11-10 composição farmacêutica BR112012011126A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0919650.2A GB0919650D0 (en) 2009-11-10 2009-11-10 Pharmaceutical composition
PCT/GB2010/051870 WO2011058351A2 (en) 2009-11-10 2010-11-10 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR112012011126A2 true BR112012011126A2 (pt) 2017-12-12

Family

ID=41502143

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011126A BR112012011126A2 (pt) 2009-11-10 2010-11-10 composição farmacêutica

Country Status (11)

Country Link
US (1) US9358219B2 (pt)
EP (1) EP2498770B1 (pt)
CN (1) CN102711751B (pt)
AU (1) AU2010317732B2 (pt)
BR (1) BR112012011126A2 (pt)
CA (1) CA2776797C (pt)
ES (1) ES2724173T3 (pt)
GB (1) GB0919650D0 (pt)
NZ (1) NZ599599A (pt)
TW (1) TWI463980B (pt)
WO (1) WO2011058351A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085589A2 (en) 2009-01-22 2010-07-29 G&H Brands Llc Desensitizing drug product
WO2012150891A1 (en) * 2011-05-02 2012-11-08 Lipidor Ab Composition for administration of a pharmacologically or cosmetically active agent onto a surface of a living organism

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
FR2737118B1 (fr) * 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
FR2740038B1 (fr) * 1995-10-20 1998-01-02 Lafon Labor Composition pour l'administration transdermique
WO2001054679A2 (en) * 2000-01-27 2001-08-02 Children's Hospital Research Foundation Transdermal composition containing an anesthetic and a vasodilator agent
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
FR2867682B1 (fr) 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
FR2871697B1 (fr) * 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
FR2887150B1 (fr) 2005-06-17 2007-08-03 Galderma Res & Dev Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
CA2649895C (en) * 2006-04-19 2013-03-26 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation

Also Published As

Publication number Publication date
CA2776797C (en) 2018-02-20
WO2011058351A3 (en) 2011-12-08
WO2011058351A2 (en) 2011-05-19
CN102711751A (zh) 2012-10-03
TW201116274A (en) 2011-05-16
CN102711751B (zh) 2015-11-25
ES2724173T3 (es) 2019-09-06
US9358219B2 (en) 2016-06-07
NZ599599A (en) 2014-06-27
CA2776797A1 (en) 2011-05-19
EP2498770B1 (en) 2019-02-27
GB0919650D0 (en) 2009-12-23
TWI463980B (zh) 2014-12-11
AU2010317732A1 (en) 2012-05-10
EP2498770A2 (en) 2012-09-19
US20120248142A1 (en) 2012-10-04
AU2010317732B2 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
BR112014027039A2 (pt) formulação farmacêutica tópica não aquosa; uso de formulação farmacêutica não aquosa; formulação não aquosa; e método
CL2014003278A1 (es) Compuestos derivados de tetrahidropirazolopirimidina, antagonistas o inhibidores de receptores similares a toll 7 y/u 8; mezcla racemica; composcion farmaceutica que los comprende; y metodo para el tratamiento de lupus eritematoso sistemico o lupus.
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
BR112015032062A8 (pt) aduto de aceptor de michael contendo enxofre, composição, aduto de aceptor de michael contendo enxofre terminado por hidroxila e aduto contendo enxofre terminado por amina
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2014003215A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion
CL2014003216A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion.
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
BRPI0819175A2 (pt) Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
CL2013001942A1 (es) Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso.
BR112016023872A2 (pt) composição de resina adequada para impressão e método de impressão com o uso da mesma
BRPI0719277A2 (pt) Formulação fitossanitária concentrada, utilização da formulação e composição solvente compreendendo uma mistura de solventes
EP3274548A4 (en) METHODS AND COMPOSITIONS FOR INJECTING ACTIVE SOLUTIONS OF HIGH CONCENTRATION AND / OR HIGH VISCOSITY
EP3575380A4 (en) LIQUID CRYSTAL ALIGNMENT AGENT POLYMER, LIQUID CRYSTAL ALIGNMENT COMPOSITION COMPRISING THE SAME, AND LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME
WO2018141941A3 (en) Methods and systems for improving stability of pre-vapor formulations of e-vaping devices
BR112015025798A2 (pt) composição lubrificante e método para lubrificar um dispositivo mecânico
BR112012033773A2 (pt) composição de formulação agroquímica,e, método para usar uma composição de formulação agroquímica.
GT201000102A (es) Producto de dispersión sólida de drogas basadas en n-aril urea
BR112017004745A2 (pt) adição a um aplicador médico
BR112019008280A2 (pt) solução farmacêutica de hidrocortisona, método para preparar a solução farmacêutica e kit de injeção
BR112012011126A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]